TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02432976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al.
Study: NCT04481815

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Methotrexate
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Study: NCT06395194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac outcomes on treatment with valsartan
Description: Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.
Study: NCT03231514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All groups will participate in a standardized exercise intervention.
Study: NCT02197325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSO
Description: Pressure controlled Intermittent Coronary Pressure Occlusion
Study: NCT06395194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac outcomes on treatment with amlodipine
Description: Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.
Study: NCT02131363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ingrowing Toenail Treatment Kit
Description: detailed in arm description
Study: NCT02376777

Intervention type: OTHER
Intervention: Follow up
Description: each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)

Intervention type: OTHER
Intervention: Follow up
Description: each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
Study: NCT04757792

Intervention type: OTHER
Intervention: File inquiry
Description: Data extraction out of file registry

Intervention type: OTHER
Intervention: File inquiry
Description: Data extraction out of file registry

Intervention type: OTHER
Intervention: File inquiry
Description: Data extraction out of file registry

Intervention type: OTHER
Intervention: File inquiry
Description: Data extraction out of file registry
Study: NCT01358344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg delayed-release tablet administered orally in the morning of Days 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg delayed-release tablet administered orally in the morning of Days 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 530348 (high percentage)
Description: 2.5 mg tablet containing \~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 530348 (standard percentage)
Description: 2.5 mg tablet containing \~23% API as free base (STANDARD) administered orally on the morning of Day 5
Study: NCT00080951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT01935076

Intervention type: BEHAVIORAL
Intervention: Neonatal exposure to maternal obesity

Intervention type: BEHAVIORAL
Intervention: Neonatal exposure to maternal obesity
Study: NCT01111864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortification with iron and micronutrients
Description: Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fortification with iron and micronutrients
Description: Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sprinkles
Description: Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
Study: NCT02604420

Intervention type: DRUG
Intervention: eculizumab
Study: NCT04320420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~* 3 supervised APA sessions/week on site:~  * two muscle strengthening sessions, stretching, flexibility in the gym~ * a cardio session (Nordic Walking: outdoors)~* at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~* 2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~* If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~* the first 3 months:~  * 2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~ * 1-hour cardio session/week independently~* the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions
Study: NCT02810886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-(HBED-CC)-PSMA
Description: 68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
Study: NCT01507337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: A single dose of 1 mg administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: A single dose of 1 mg administered subcutaneously (under the skin)
Study: NCT04044261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emotion induction using video
Description: Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
Study: NCT01855685

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: X vivo gene therapy
Description: Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
Study: NCT00738049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darusentan 100 mg
Description: All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darusentan 100 mg
Description: All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
Study: NCT00461786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 900 mg/m2, intravenous (IV), every 21 days, until disease progression
Study: NCT02761512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50 mg QD
Description: CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100 mg QD
Description: CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30 mg QD
Description: Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
Study: NCT01200810

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given orally
Study: NCT04486794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane®
Description: Hyaluronic acid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane®
Description: Hyaluronic acid
Study: NCT04135235

Intervention type: DRUG
Intervention: TAF
Description: Propofol tenofovir fumarate

Intervention type: DRUG
Intervention: TDF
Description: Dipirofurate fumarate tenofovir
Study: NCT02897791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written evaluations
Description: answering questions about pictures and stories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written evaluations
Description: answering questions about pictures and stories
Study: NCT01194648

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: assessment of therapy complications

Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-intensity focused ultrasound ablation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: multiparametric magnetic resonance imaging

Intervention type: PROCEDURE
Group type: OTHER
Intervention: quality-of-life assessment
Study: NCT03904927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation, Surgery or Radiofrequency ablation
Description: Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: 1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: 1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy.
Study: NCT01121289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1218
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1218
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1218
Description: 0.4 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1218
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1218
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study: NCT04305392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: orally SHR4640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: orally SHR4640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: orally SHR4640
Study: NCT01444716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study: NCT01717638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
Study: NCT02800252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 plus aspirin before periodontal therapy
Description: Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
Study: NCT03976700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei Jianpi granule
Description: Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bufei Jianpi granule
Description: Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
Study: NCT00594555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAG
Description: Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days
Study: NCT02013414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D ultrasound-guided biopsy
Description: Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
Study: NCT04288791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equia Forte Fil
Description: Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equia Forte Fil
Description: Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zirconomer Improved
Description: Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zirconomer Improved
Description: Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
Study: NCT01580644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0187 prodrug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0187 prodrug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0187 prodrug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0187 prodrug
Study: NCT02469909

Intervention type: OTHER
Group type: OTHER
Intervention: Overnight observation
Description: patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-discharge evaluation
Description: After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
Study: NCT03963882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RH
Description: Radical hysterectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Description: Concurrent radiochemotherapy